Goldman Sachs Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $13
XP Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Neutral on XP, Lowers Price Target to $13
XP Analyst Ratings
UBS Upgrades XP Inc(XP.US) to Buy Rating, Cuts Target Price to $16
Banco Santander Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $13
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $18
XP Cut to Neutral From Buy by B of A Securities
XP Analyst Ratings
BofA Securities Downgrades XP Inc(XP.US) to Hold Rating, Cuts Target Price to $16
BofA Securities Downgrades XP to Neutral From Buy, Price Target Is $16
XP Is Maintained at Equal-Weight by Morgan Stanley
XP Analyst Ratings
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $21
XP Inc. Hold Rating: EPS Adjustments and Price Target Reduction Highlight Cautious Outlook
UBS Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $19
BofA Securities Maintains XP Inc(XP.US) With Buy Rating, Maintains Target Price $25
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Maintains Target Price $24
J.P. Morgan Maintains XP Inc(XP.US) With Buy Rating, Cuts Target Price to $29
XP Analyst Ratings